Edition:
United States

Gilead & Galapagos Announce Filgotinib Meets Primary Endpoint In First Phase 3 Study In Rheumatoid Arthritis


Tuesday, 11 Sep 2018 04:05pm EDT 

Sept 11 (Reuters) - Galapagos NV ::GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY AND ALL KEY SECONDARY ENDPOINTS IN FIRST PHASE 3 STUDY IN RHEUMATOID ARTHRITIS.GALAPAGOS NV - BOTH FILGOTINIB DOSES ALSO ACHIEVED ALL KEY SECONDARY EFFICACY ENDPOINTS.GALAPAGOS NV - TOLERABILITY OF FILGOTINIB WAS CONSISTENT WITH PREVIOUSLY REPORTED STUDIES.GALAPAGOS - FILGOTINIB WAS GENERALLY WELL-TOLERATED IN FINCH 2 TRIAL, WITH NO NEW SAFETY SIGNALS VERSUS THOSE REPORTED IN PREVIOUS TRIALS OF FILGOTINIB.